Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term targeted therapy. Found 15 abstracts

Iyer P, Chen MH, Goyal L, Denlinger CS. Targets for therapy in biliary tract cancers: the new horizon of personalized medicine. Chinese clinical oncology. 2020 Feb;9(1):7.
Nemunaitis J, Bauer S, Blay JY, Choucair K, Gelderblom H, George S, Schoffski P, Mehren MV, Zalcberg J, Achour H, Ruiz-Soto R, Heinrich MC. Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib. Future Oncol. 2020 Jan;16(1):4251-64.
Deneka AY, Boumber Y, Beck T, Golemis EA. Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC). Cancers. 2019 Sep 03;11(9).   PMCID: PMC6769513
Gabbasov R, Benrubi ID, O'Brien SW, Krais JJ, Johnson N, Litwin S, Connolly DC. Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition. Cancer Biol Ther. 2019 Mar 30;20(7):1035-45.   PMCID: PMC6606007
Zhang P, Kiseleva AA, Korobeynikov V, Liu H, Einarson MB, Golemis EA. Microscopy-Based Automated Live Cell Screening for Small Molecules That Affect Ciliation. Frontiers in genetics. 2019 Jan;10:75.   PMCID: PMC6379280
Moore KN, Borghaei H, O'Malley DM, Jeong W, Seward SM, Bauer TM, Perez RP, Matulonis UA, Running KL, Zhang X, Ponte JF, Ruiz-Soto R, Birrer MJ. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in patients with solid tumors. Cancer. 2017 Aug 15;123(16):3080-7.
Uzzo RG, Horwitz EM, Plimack ER. Fox Chase Cancer Center's Genitourinary Division: a national resource for research, innovation and patient care. Future Oncol. 2016 Feb 17;12(7):887-91.
Shagisultanova E, Dunbrack RL, Golemis EA. Issues in interpreting the in vivo activity of Aurora-A. Expert Opin Ther Targets. 2015 Feb;19(2):187-200.   PMCID: Pmc4294965
Fury MG, Sherman E, Lisa D, Agarwal N, Algazy K, Brockstein B, Langer C, Lim D, Mehra R, Rajan SK, Korte S, Lipson B, Yunus F, Tanvetyanon T, Smith-Marrone S, Ng K, Xiao H, Hague S, Pfister DG. A Randomized Phase II Study of Cetuximab Every 2 Weeks at Either 500 or 750 mg/m(2) for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer. Journal of the National Comprehensive Cancer Network. 2012 Nov;10(11):1391-8.   PMCID: no NIH
Giordano A, Gao H, Anfossi S, Cohen E, Mego M, Lee BN, Tin S, De Laurentiis M, Parker CA, Alvarez RH, Valero V, Ueno NT, De Placido S, Mani SA, Esteva FJ, Cristofanilli M, Reuben JM. Epithelial-Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer. Molecular Cancer Therapeutics. 2012 Nov;11(11):2526-34.   PMCID: PMC 3500676
Banumathy G, Cairns P. Signaling pathways in renal cell carcinoma. Cancer Biology & Therapy. 2010 Oct;10(7):658-64.   PMCID: PMC3093809
Blay JY, von Mehren M, Blackstein ME. Perspective on Updated Treatment Guidelines for Patients With Gastrointestinal Stromal Tumors. Cancer. 2010 Nov;116(22):5126-37.   PMCID: NIH funded
Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005 Nov 14;24(50):7455-64.
Kruh GD. Introduction to resistance to anticancer agents. Oncogene. 2003 Oct;22(47):7262-4.
Cohen SJ, Meropol NJ. Drug development in pancreatic cancer - Finally, biology begets therapy. International Journal of Gastrointestinal Cancer. 2002 Jan;32(2-3):91-106.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term targeted therapy

targeted therapy tyrosine kinase inhibitor advanced colorectal-cancer kidney cancer growth-factor receptor clinical trial ripretinib prostate cancer PARP inhibitor Kit term-follow-up monoclonal-antibody phosphorylation AKT breast cancers beta-catenin first-line therapy endothelial genitourinary cancer antibody-drug conjugate ciliary disassembly vaccines platinum-based circulating tumor-cells protein-kinase-b Aurora-A kinases dose imatinib PKB kinases drugs c-kit cholangiocarcinoma Her-2 carcinomas frequent activation RCC bladder cancer phase-i trial Adpkd epigenetics growth-factor FTI screening chemotherapy induced apoptosis Fox Chase Cancer Center high content imaging genetics neu phase 1 gene-expression progression phase-iii antitumor-activity protooncogene clinical trials colony-stimulating factor survival allosteric activation EGFR pancreatic cancer Phase III trial precision medicine akt irinotecan phosphatidylinositol 3-kinase met apoptosis multicenter imatinib mesylate randomized-trial tuberous-sclerosis cancer farnesyl-protein transferase plus cetuximab dose-escalation immunotherapy hypoxia-inducible factor-1 carcinoma small cell lung cancer oncogenes phenotype HSP90 inhibitor VEGF antibody-drug conjugates tumor-cells Aurka tyrosine-kinase inhibitor receptor tyrosine kinase tumor suppressor genes mTOR disease gist human malignancy biweekly cetuximab ovarian-cancer signaling pathways Biliary tract cancer (BTC) tumor-suppressor matrix metalloproteinase inhibitors tumor-cell growth Nedd9 Pdgfra human pancreatic-cancer prostate intraepithelial neoplasia chemosensitivity aurora kinase A Dcc-2618 heat shock protein 90 matrix-metalloproteinase inhibitor stromal gastrointestinal-tumors-imatinib-practice guideline-protein tyrosine-kinases-sunitinib gastrointestinal stromal tumor sarcoma Ovarian cancer Pak surgical-management folate receptor Tpx2
Last updated on Thursday, August 13, 2020